Slingshot members are tracking this event:

AbbVie (ABBV) Releases Results from Three Pivotal Studies of Pan-Genotypic Chronic Hepatitis B Virus Infection Regimen Glecaprevir/Pibrentasvir to be Presented at The Liver Meeting in Boston, November 11 - 15

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Edurance-1, Endurance-3, Surveyor-2, Glecaprevir, Pibrentasvir, Pivotal Studies, Pan-genotypic, Chronic Hepatitis B Virus Infection, Hbv, The Liver Meeting